PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PerkinElmer (PKI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Growth Stocks to Buy for January 21st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 21st
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
3 Reasons Why PerkinElmer (PKI) Is a Great Growth Stock
by Zacks Equity Research
PerkinElmer (PKI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why PerkinElmer (PKI) Could Beat Earnings Estimates Again
by Zacks Equity Research
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Perion (PERI) Announces Encouraging Preliminary Q4 Results
by Zacks Equity Research
Perion Network (PERI) posts upbeat fourth-quarter and 2020 preliminary financial results, on the back of strength in the advertising business and synergies from recent acquisitions.
4 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, WAT, PKI, and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
Top Ranked Growth Stocks to Buy for January 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 20th
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
by Sriparna Ghosal
Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing
by Zacks Equity Research
PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing
by Zacks Equity Research
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout
by Zacks Equity Research
The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
Top Ranked Growth Stocks to Buy for January 14th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 14th
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
by Zacks Equity Research
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
PerkinElmer (PKI) to Buy Oxford Immunotec for $591 million
by Zacks Equity Research
PerkinElmer's (PKI) acquisition of Oxford Immunotec will expand its portfolio of advanced infectious disease testing solutions.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Has PerkinElmer (PKI) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (PKI) Outperforming Other Computer and Technology Stocks This Year?
NCR Expands E-Commerce Capabilities With Freshop Acquisition
by Zacks Equity Research
NCR acquires Freshop to boost its retail business with the integration of the latter's e-commerce solution to its retail core point-of-sale (POS) software platform.
Stratasys (SSYS) Completes Origin Buyout to Fuel 3D Printing
by Zacks Equity Research
Stratasys (SSYS) completes the previously announced buyout of Origin, thereby aiding the expansion of its 3D printing portfolio and securing its leadership in the mass production parts market.
Mercury (MRCY) Completes the Buyout of Physical Optics
by Zacks Equity Research
Mercury (MRCY) completes the previously announced acquisition of Physical Optics, thereby driving the expansion of its robust product portfolio.